Associated Papers
Comprehensive molecular characterization of Rho GTPases and their regulators across human cancers.
Luo S et al.
International Journal of Cancer, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
A Comparative Genomic Study of Conventional and Undifferentiated Melanoma.
Fischer GM et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Assessing the mechanism of fast-cycling cancer-associated mutations of Rac1 small Rho GTPase.
Parise A et al.
Protein Science : a Publication of the Protein Society, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN et al.
Jama Network Open, 2023
Utilization of cytologic cell blocks for targeted sequencing of solid tumors.
Vormittag-Nocito E et al.
Cancer Medicine, 2023
The landscape of driver mutations in cutaneous squamous cell carcinoma.
Chang D et al.
Npj Genomic Medicine, 2021
Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing-A Prospective Feasibility Study.
Berger M et al.
Cancers, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
Kang T et al.
Breast Cancer Research : Bcr, 2020
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C et al.
Nature Communications, 2020
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
Lionarons DA et al.
Cancer Cell, 2019
De novo missense variants in RAC3 cause a novel neurodevelopmental syndrome.
Costain G et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Araiza-Olivera D et al.
Oncogene, 2018
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
RAC1 P29S regulates PD-L1 expression in melanoma.
Vu HL et al.
Pigment Cell & Melanoma Research, 2015
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV et al.
Nature Communications, 2014
Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ et al.
Pigment Cell & Melanoma Research, 2014